Alexander I. Velasquez 9/8/25 Alexander I. Velasquez 9/8/25

Niagen Bioscience: A Great Company Suffering From Stock Dilution

Niagen Bioscience (NASDAQ:NAGE) posted strong Q2 earnings with positive cash flow and a debt-free balance sheet. Yet years of stock dilution weigh heavily on intrinsic value, with my DCF model estimating fair value at $4.04 per share. Despite product strength, I rate the stock a cautious hold.

Alexander I. Velasquez 6/16/25 Alexander I. Velasquez 6/16/25

Live Nation Entertainment: A DCF-Driven Bear Case

Live Nation (NYSE:LYV) stock trades nearly 48% above its intrinsic value of $93.51 per share, based on a detailed enterprise DCF model. With Q1 revenue down 11.1% YoY and legal pressure mounting from the DOJ and FTC, the company’s vertically integrated business model could be at risk. I maintain a sell rating.